Vertex's revenue was $2.96 billion in the second quarter of 2025, beating the consensus forecast by $58 million. Click here ...
Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...
Vertex also announced enrollment completion of the IA cohort of AMPLITUDE, a global Phase 2/3 clinical trial designed to assess the impact of ...
Zacks Investment Research on MSN
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
Vertex Pharmaceuticals (VRTX) ended the recent trading session at $381.87, demonstrating a +1.39% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.5%. At ...
Finance is fast becoming one of the most high-impact areas for AI adoption. From anomaly detection to predictive compliance, today’s AI-powered tools help turn complexity into easily digestible data ...
Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of ...
The FDA granted breakthrough therapy designation to a Vertex Pharmaceuticals kidney disease drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback